ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Gabriel Oliveira Sawakuchi
Matched on ORCID iD 0000-0001-5560-0650; OpenAlex author ID A5003863043. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 37
2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 7
- Differentiation Stage Predicts Radiosensitivity in Mesenchymal-Like Pancreatic Cancer. Last author DOI 10.1016/j.ijrobp.2025.03.034↗
- Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
- Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-1785↗
- Dose escalation for locally advanced pancreatic cancer: How high can we go? Co-author DOI 10.1016/j.adro.2018.07.008↗
- Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Co-author DOI 10.1016/j.ijrobp.2016.10.046↗
- EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced Pancreatic Cancer Co-author DOI 10.1101/195610↗
- Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolida… Co-author DOI 10.1016/j.ijrobp.2015.12.003↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lauren Elizabeth Colbert · 4 shared papers, 2017–2023 · strength 0.34
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Cullen M. Taniguchi · 4 shared papers, 2017–2023 · strength 0.34
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Eugene Jon Koay · 3 shared papers, 2018–2023 · strength 0.27
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Dose escalation for locally advanced pancreatic cancer: How high can we go? DOI 10.1016/j.adro.2018.07.008↗
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Matthew H. G. Katz · 3 shared papers, 2016–2023 · strength 0.22
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? DOI 10.1016/j.ijrobp.2016.10.046↗
- Paper Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiv… DOI 10.1016/j.ijrobp.2015.12.003↗
- Robert A. Wolff · 3 shared papers, 2016–2023 · strength 0.22
- Paper Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, r… DOI 10.1016/s1470-2045(23)00478-3↗
- Paper Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? DOI 10.1016/j.ijrobp.2016.10.046↗
- Paper Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiv… DOI 10.1016/j.ijrobp.2015.12.003↗
- Joseph M. Herman · 2 shared papers, 2018–2023 · strength 0.20
- Shalini Moningi · 2 shared papers, 2018–2023 · strength 0.20
- Ting‐Shi Su · 1 shared paper, 2025 · strength 0.20
- Tara N. Fujimoto · 2 shared papers, 2017–2019 · strength 0.15
- Paper Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. DOI 10.1158/0008-5472.can-18-1785↗
- Paper EGLN Inhibition Reduces Gastrointestinal Radiation Toxicity and Improves Survival in a Murine Model of Locally Advanced… DOI 10.1101/195610↗
- Brian G. Czito · 1 shared paper, 2023 · strength 0.12
- Dae Won Kim · 1 shared paper, 2023 · strength 0.12
- Jessica M. Frakes · 1 shared paper, 2023 · strength 0.12
- Joseph Abi Jaoude · 1 shared paper, 2023 · strength 0.12
- Todd Anthony Aguilera · 1 shared paper, 2023 · strength 0.12
- Manisha Palta · 1 shared paper, 2023 · strength 0.12
- Vincent Bernard · 1 shared paper, 2023 · strength 0.12
- Rebecca S. Slack Tidwell · 1 shared paper, 2023 · strength 0.12
- Sarah E. Hoffe · 1 shared paper, 2023 · strength 0.12
- Mokenge Peter Malafa · 1 shared paper, 2023 · strength 0.12
- Ethan Bernard Ludmir · 1 shared paper, 2023 · strength 0.12
- Manoop S. Bhutani · 1 shared paper, 2023 · strength 0.12
- Ying Yuan · 1 shared paper, 2023 · strength 0.12
- Shubham Pant · 1 shared paper, 2023 · strength 0.12
- Ching-Wei David Tzeng · 1 shared paper, 2023 · strength 0.12
- Milind M. Javle · 2 shared papers, 2016–2017 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.